A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose aspirin ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Anticoagulants and antiplatelet agents pose a great risk in patients undergoing surgery. Because these products inhibit at least one, and often multiple, factors in the clotting cascade ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

[55] Perhaps the most difficult decision to be made in the management of a patient with a GI bleed after PCI is how to manage their antiplatelet and anticoagulant regimen. There are no data that ...

Opens in a new tab or window Direct oral anticoagulants were associated ... resulting in use of more medications such as antiplatelets (17.8% vs 13%), beta-blockers (58.7% vs 47.5%), and calcium ...

Direct oral anticoagulants are effective and safe for the prevention ... and peptic ulcer disease), medication exposure at baseline (eg, aldosterone antagonists, antiplatelet agents, proton‐pump ...

Several factors play a role in the development of NSTEMI. Stable plaque in the arteries can lead to stenosis or narrowing of the arteries. 2 Vasospasm in the muscles surrounding blood vessels can lead ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...